We then treated cells with SC78, an AKT agonist, to detect whether CCDC-PA at 1:5 ratio (a concentration that showed a significant effect in most results) inhibited oral cancer through the AKT signaling pathway. Here, AKT1 is linked to lip and oral cavity carcinoma.